Ruxolitinib or Placebo With Capecitabine in Metastatic Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
J. Clin. Oncol 2015 Sep 08;[EPub Ahead of Print], HI Hurwitz, N Uppal, SA Wagner, JC Bendell, JT Beck, SM Wade, JJ Nemunaitis, PJ Stella, JM Pipas, ZA Wainberg, R Manges, WM Garrett, DS Hunter, J Clark, L Leopold, V Sandor, RS LevyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.